Browse Trials

➤

In response to COVID-19, some breast cancer trials have temporarily stopped enrolling new patients. Use the contact information in our trial listings to call or email the research site for information about a trial's status.

Visit COVID-19 & Cancer Clinical Trials on Metastatic Trial Talk for regularly updated information about clinical trials during the coronavirus pandemic.

Currently viewing trials
(Last updated: July 07, 2020)

and or

Reset

Zip Code:

Narrow my choices:

Radius (miles): All U.S.

All U.S.

Early stage

Advanced

Treatment

Non-treatment

Phase I II III

Display Only New Trials

Click here to view online studies and trials that do not require site visits

NEAREST SITE: 3 miles
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco,CA

VISITS: Number of visits unavailable, up to 2 years

PHASE: II

NCT ID: NCT03094052

Diarrhea Prevention for People With HER2+ Breast Cancer Receiving Neratinib Alone or With Herceptin

An Open Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early Stage HER2+ Breast Cancer Treated With Adjuvant Trastuzumab and Neratinib Followed by Neratinib Monotherapy, and Intensive Anti-diarrhea Prophylaxis Scientific Title

Purpose

To study whether taking anti-diarrhea medication can help prevent diarrhea in people being treated with neratinib (Nerlynx®) alone or in combination with trastuzumab (Herceptin®).

Who is this for?

People with stage II or stage III, HER2 positive (HER2+) breast cancer who have finished chemotherapy and radiation therapy and who are still receiving adjuvant trastuzumab (Herceptin®) or are within 1 year of finishing trastuzumab (Herceptin®). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, as indicated by your doctor</li> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®), by mouth, daily, up to 2 years</li> <li class="seamTextUnorderedListItem">Loperamide, by mouth, daily for 6 weeks, then as needed</li> <li class="seamTextUnorderedListItem">Crofelemer (Mytesi®), by mouth, daily for 6 weeks, then as needed</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The two approved HER2-targeted drugs used in this trial are trastuzumab (Herceptin®) and neratinib (Nerlynx®)</li> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®) is known to cause diarrhea.</li> <li class="seamTextUnorderedListItem">Crofelemer (Mytesi®) is a medicine used to prevent diarrhea in people being treated for HIV/AIDS. </li> <li class="seamTextUnorderedListItem">Loperamide (Immodium) is an over-the-counter medication used to prevent and treat diarrhea.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03094052' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.fulyzaq.com/' target='_blank'>Drug Company Information Page: Crofelemer (Mytesi)</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.onclive.com/web-exclusives/fda-accepts-neratinib-nda-for-her2positive-breast-cancer' target='_blank'>OncLive: Neratinib</a> </li></ul>

NEAREST SITE: 3 miles
Kaiser Permanente-San Francisco
San Francisco,CA

VISITS: Number of visits unavailable

PHASE: III

NCT ID: NCT02822573

Aricept to Improve Memory Loss in Survivors Who Had Chemotherapy

A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors With Cognitive Impairment Scientific Title

Purpose

To see whether a drug used to treat memory problems helps breast cancer survivors.

Who is this for?

Women with breast cancer who completed treatment with chemotherapy between 1 and 5 years ago. You must be experiencing memory problems. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 to 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Memory questionnaires</li> <li class="seamTextUnorderedListItem">Donepezil (Aricept®), by mouth, daily, for 6 months</li> <li class="seamTextUnorderedListItem">followed by 3 months of no treatment</li> </ul> Group 2: Placebo <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Memory questionnaires</li> <li class="seamTextUnorderedListItem">Placebo, by mouth, daily, for 6 months</li> <li class="seamTextUnorderedListItem">followed by 3 months of no treatment</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The study will compare the safety and effects of the drug, donepezil (Aricept®), to a placebo. </li> <li class="seamTextUnorderedListItem">The focus will be on the effect the drug has on memory skills.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02822573' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/druginfo/meds/a697032.html' target='_blank'>MedlinePlus: Donepezil</a> </li></ul>

NEAREST SITE: 3 miles
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco,CA

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT02400476

Neratinib & Imodium after Herceptin for HER2+ Stage I-III Breast Cancer

A Study Looking the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide Scientific Title

Purpose

To see whether women with HER2 positive tumors who take Imodium along with neratinib experience less diarrhea.

Who is this for?

Women with stage I, stage II, or stage III HER2 positive breast cancer who have previously received Herceptin. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

All participants will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neratinib, by mouth, daily</li> <li class="seamTextUnorderedListItem">Loperamide, by mouth, daily</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neratinib is a targeted therapy that is currently being studied in clinical trials for HER2 positive breast cancer. </li> <li class="seamTextUnorderedListItem">These studies have found that diarrhea is one of the common side effects of neratinib. </li> <li class="seamTextUnorderedListItem">Loperamide (Imodium) is an over-the-counter medication used to prevent and treat diarrhea.</li> </ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02400476' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.medscape.org/viewarticle/586897' target='_blank'>Medscape.org: Neratinib for HER2-positive Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.webmd.com/drugs/2/drug-4789-4025/loperamide-oral/loperamide-oral/details' target='_blank'>WebMD: Loperamide</a> </li></ul>

NEAREST SITE: 22 miles
Contra Costa Regional Medical Center
Martinez,CA

VISITS: Coincides with chemotherapy treatment

PHASE: NA

NCT ID: NCT02728596

CSF to Prevent Neutropenia (Infection) Caused by Chemotherapy (TrACER)

A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as a Prophylaxis for Patients Receiving Chemotherapy With Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) Scientific Title

Purpose

To evaluate the benefits of using guidelines that have been developed to direct specific patients who are receiving certain types of chemotherapy to receive CSF to reduce their risk of neutropenia.

Who is this for?

People who are receiving chemotherapy as part of breast cancer treatment and have an intermediate risk of developing neutropenia (a low-white blood cell count). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CSF while receiving chemotherapy treatment </li> <li class="seamTextUnorderedListItem">Quality-of-Life Assessments</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Patients who develop neutropenia--a fever and low white cell blood count--are at increased risk of developing an infection. </li> <li class="seamTextUnorderedListItem">CSF (Colony-stimulating factors) are medications sometimes given to patients receiving chemotherapy to prevent neutropenia. </li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02728596' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.net/navigating-cancer-care/side-effects/neutropenia' target='_blank'>Cancer.net: Neutropenia</a> </li><li class='seamTextUnorderedListItem'><a href='http://chemocare.com/chemotherapy/side-effects/fever-neutropenic-fever-and-their-relationship-to-chemotherapy.aspx' target='_blank'>ChemoCare: Fever, Neutropenic Fever, and their Relationship to Chemotherapy</a> </li></ul>

NEAREST SITE: 22 miles
Contra Costa Regional Medical Center
Martinez,CA

VISITS: Number of visits unavailable

PHASE: III

NCT ID: NCT03418961

Carvedilol to Prevent Heart Problems in Patients with Metastatic HER2+ Breast Cancer

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients With Metastatic HER-2+ Breast Cancer, Phase III Scientific Title

Purpose

To investigate whether giving people with HER2+ breast cancer a beta-blocker can help prevent heart problems caused by cancer treatments.

Who is this for?

People with HER2 positive metastatic (stage IV) breast cancer who are starting or continuing a trastuzumab-based anitHER2 therapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 3 groups: Group 1: Intervention <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Carvedilol, by mouth, daily for up to 2 years</li> </ul> Group 2: Standard of care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No intervention</li> </ul> Group 3: If you are already taking taking a beta blocker, ARB, or ACE inhibitor <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Observation for up to 2 years</li></ul>
The beta-blocker being used in this study is carvedilol. It is used to treat heart failure and high blood pressure.
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03418961' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/treatment/side_effects/heart_probs' target='_blank'>Breastcancer.org: Heart Problems</a> </li></ul>

NEAREST SITE: 348 miles
USC Norris Comprehensive Cancer Center
Los Angeles,CA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT01802346

Low-Calorie Diet To Reduce Side Effects of Chemotherapy

A Randomized, Phase II Clinical Trial of a Controlled Diet Prior to Selected Chemotherapy Treatment in Breast and Prostate Cancer to Evaluate the Impact on Toxicity and Efficacy Scientific Title

Purpose

To study whether patients with breast cancer who eat a controlled low-calorie diet will have fewer side effects and a better response to chemotherapy than patients who eat a normal diet. (This trial also is enrolling men with prostate cancer.)

Who is this for?

People with breast cancer Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

Participants will be randomly assigned to 1 of 2 groups: Group 1: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Eat a special low-calorie diet during before, during and after chemotherapy (All food provided)</li> </ul> Group 2: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Eat a normal diet, receive dietary advice from a nutritionist</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Chemotherapy drugs attack cells that are rapidly dividing, which is why they are an effective cancer treatment. </li> <li class="seamTextUnorderedListItem">However, other cells in the body that also divide rapidly, like those in the bone marrow, mouth, intestines, and hair follicles, are also likely to be affected by chemotherapy®which can lead to side effects. </li> <li class="seamTextUnorderedListItem">It is possible that eating a low-calorie diet may reduce chemotherapy-related side effects as well as improve how the tumor responds to treatment.</li> </ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01802346' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/treatment/chemotherapy/side_effects' target='_blank'>BreastCancer.org: Chemotherapy Side Effects</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-treating-chemotherapy' target='_blank'>Cancer.gov: Chemotherapy</a> </li></ul>

NEAREST SITE: 348 miles
USC / Norris Comprehensive Cancer Center
Los Angeles,CA

VISITS: 3 visits a week for 12 weeks

PHASE: NA

NCT ID: NCT02454777

High-Intensity Interval Training for Patients with Early-Stage Breast Cancer

High-Intensity Interval Training (HIT) for Breast Cancer Patients During Trastuzumab Use Scientific Title

Purpose

To determine if women receiving chemotherapy and Herceptin can take part in high-intensity interval training to improve their heart and overall health.

Who is this for?

Women with stage I, stage II, or stage III breast cancer who are planning to receive trastuzumab (Herceptin®) and chemotherapy. You must speak English and/or Spanish and be between the ages of 30 and 60. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 3 groups: Group 1: High-Intensity Interval Training <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">High-intensity training for 30 minutes, 3 times a week, for 12 weeks </li> </ul> Group 2: Moderate-Intensity Interval Training <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Moderate-intensity training for 30 minutes, 3 times a week, for 12 weeks </li> </ul> Group 3: No Intervention <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Maintain current sedentary activity level (less than 60 minutes of total exercise per week), for 12 weeks </li> <li class="seamTextUnorderedListItem">Document weekly activity in an exercise log </li> <li class="seamTextUnorderedListItem">Option to participate in the moderate-intensity exercise program after 12 weeks</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Herceptin (a HER2 targeted therapy) may cause heart problems in some patients. </li> <li class="seamTextUnorderedListItem">Aerobic exercise, which can improve heart functioning, may help reduce the risk of these heart problems developing. </li> <li class="seamTextUnorderedListItem">Aerobic exercise may also reduce risk of recurrence and reduce fatigue.</li> <li class="seamTextUnorderedListItem">High-intensity interval training involves short bursts of high-intensity efforts followed by periods of recovery.</li> <li class="seamTextUnorderedListItem">High-intensity interval training may allow patients who are unable to exercise for a long period of time to remain physically active.</li> </ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02454777' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 386 miles
Loma Linda Medical Center
Loma Linda,CA

VISITS: 2 visits weekly, for 6 weeks

PHASE: NA

NCT ID: NCT03272919

Physical Therapy to Prevent Peripheral Neuropathy in Women with Early-Stage Breast Cancer

Chemotherapy Induced Peripheral Neuropathy (CIPN): A Pilot Study of Intraneural Facilitation for Managing Chemotherapy-Induced Peripheral Neuropathy Scientific Title

Purpose

To study whether a new physical therapy technique called intraneural facilitation can restore blood flow to damaged nerves and reduce the risk of peripheral neuropathy.

Who is this for?

Women who are newly diagnosed with early stage (stage I-III) breast cancer. You must also be planning to receive platinum- and/or taxane-based chemotherapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Intraneural facilitation (physical therapy), twice a week, for 6 weeks</li> <li class="seamTextUnorderedListItem">3 assessments (ultrasound, surveys and questionnaires) over 4.5 months</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care muscle stretching and strengthening, twice a week, for 6 weeks</li> <li class="seamTextUnorderedListItem">3 assessments (ultrasound, surveys and questionnaires) over 4.5 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You must be planning to receive platinum- and/or taxane-based chemotherapy. This includes carboplatin/Paraplatin® or cisplatin/Platinol® and/or docetaxel/Taxotere® or paclitaxel/Taxol®. </li> <li class="seamTextUnorderedListItem">Intraneural facilitation (INF) is a technique that helps improve blood flow to the nerves by widening tiny openings in nearby arteries. The improved blood flow may stimulate healing and reduce or stop nerve pain.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03272919' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 602 miles
Huntsman Cancer Institute
Salt Lake City,UT

VISITS: 2 visits over 1 week

PHASE: NA

NCT ID: NCT02317783

Using Brain Imaging to Study the Effect of Chemotherapy on the Brain

Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment Scientific Title

Purpose

To better understand chemo brain.

Who is this for?

Women with stage I, stage II, or stage II breast cancer who have completed chemotherapy between 6 months and 36 months ago. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

All participants will undergo 2 FDG-PET scans using flutemetamol over a week
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Many cancer patients have thinking and memory problems due to cancer or its treatments. </li> <li class="seamTextUnorderedListItem">The reasons for this <q>mental fog</q> referred to as chemo brain are not always known.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02317783' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://clinicaltrials.gov/ct2/show/NCT02317783?term=NCT02317783&rank=1' target='_blank'>ClinicalTrials.gov: Trial Information</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.org/treatment/treatmentsandsideeffects/physicalsideeffects/chemotherapyeffects/chemo-brain' target='_blank'>Cancer.org: Chemo Brain</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm372261.htm' target='_blank'>FDA.gov: Imaging Drug, Flutemetamol</a> </li></ul>

NEAREST SITE: 741 miles
University of Arizona
Tucson,AZ

VISITS: 2 visits within 2 months

PHASE: NA

NCT ID: NCT03661892

Syndros to Reduce Pain from Bone Metastases in Stage IV Breast Cancer

Title A Pilot Trial to Evaluate Syndros in Decreasing Opioid Requirement in Patients With Bone Metastases From Breast Cancer Scientific Title

Purpose

To identify the best dose and side effects (good and bad) of Syndros (dronabinol) when used to treat pain from bone metastasis.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the bone and have been taking an opioid for bone pain for at least 4 weeks. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Syndros (Dronabinol), by mouth, daily, for 2 months</li> <li class="seamTextUnorderedListItem">Blood and urine samples</li> <li class="seamTextUnorderedListItem">Questionnaires</li> <li class="seamTextUnorderedListItem">Weekly calls</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Syndros is an FDA-approved cannabinoid. </li> <li class="seamTextUnorderedListItem">Cannabinoids are the active chemicals in medical marijuana.</li> <li class="seamTextUnorderedListItem">Syndros is approved to treat patients receiving chemotherapy whose nausea and vomiting are not controlled by other anti-nausea therapies.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03661892' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.practicalpainmanagement.com/resources/news-and-research/fda-approves-syndros-first-liquid-form-cannabinoid-dronabinol' target='_blank'>Practical Pain Management: FDA Approves Syndros, First Liquid Form of Cannabinoid Dronabinol</a> </li><li class='seamTextUnorderedListItem'><a href='https://ww5.komen.org/BreastCancer/ManagingPainRelatedToMetastaticBreastCancer.html' target='_blank'>Practical Pain Management: FDA Approves Syndros, First Liquid Form of Cannabinoid Dronabinol</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.curetoday.com/articles/fda-approves-liquid-formulation-of-thccontaining-drug-for-cinv' target='_blank'>CureToday: FDA Approves Liquid Formulation of THC-Containing Drug for CINV</a> </li></ul>

NEAREST SITE: 1500 miles
University of Kansas Medical Center
Kansas City,KS

VISITS: Daily visits for 1 month

PHASE: NA

NCT ID: NCT02958774

Hypofractionated Radiation To Treat Regional Lymph Nodes to Reduce Lymphedema Risk

Hypofractionated Radiation Therapy for Patients With Breast Cancer Receiving Regional Nodal Irradiation Scientific Title

Purpose

To learn whether hypofractionated radiation therapy is less likely to cause lymphedema than conventional radiation therapy.

Who is this for?

Women with stage II or stage III breast cancer that has spread to the lymph nodes (node positive) who will be treated with radiation after breast cancer surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Hypofractionated radiation therapy, daily, for 1 month</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lymphedema is a swelling of the soft tissues in the arm and hand caused by a build-up of lymph fluid. </li> <li class="seamTextUnorderedListItem">Radiation therapy to the lymph nodes can result in scar tissue that blocks the lymph flow, increasing risk for lymphedema. </li> <li class="seamTextUnorderedListItem">Hypofractionated radiation therapy is a type of radiation therapy that is given at a higher dose over a shorter period of time than standard radiation therapy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02958774' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/side_effects/lymphedema' target='_blank'>Breastcancer.org: Lymphedema</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/hypofractionated-radiation-therapy' target='_blank'>NCI Dictionary of Cancer Terms: Hypofractionated radiation therapy</a> </li></ul>

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: 1 visit

PHASE: NA

NCT ID: NCT03012399

Effects of Hypnosis During Breast Cancer Surgery

Biobehavioral Effects of Hypnosis During Breast Cancer Surgery Scientific Title

Purpose

To study a relaxation method called hypnosedation.

Who is this for?

Women with DCIS or stage I breast cancer who have not yet had breast surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Hypnosedation performed by a hypnotherapist, beginning right before surgery and continuing through until your surgery ends</li> <li class="seamTextUnorderedListItem">Conscious sedation during surgery</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Empathetic conversation with a hypnotherapist right before surgery</li> <li class="seamTextUnorderedListItem">General anesthesia during surgery</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Using hypnosedation before and during breast cancer surgery may allow patients to avoid having general anesthesia.</li> <li class="seamTextUnorderedListItem">Hypnosedation is administered by a hypnotherapist, a mind-body specialist who uses words and images to help you relax during surgery.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03012399' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://abcnews.go.com/Health/Healthday/story?id=4508455&page=1' target='_blank'>ABC News: Hypnosis Article</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/treatment/comp_med/types/hypnosis' target='_blank'>Breastcancer.org: Hypnosis</a> </li></ul>

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: 10-12 visits over 8 weeks

PHASE: II

NCT ID: NCT02754752

Acupuncture for Relieving Severe Post-Mastectomy Pain

Randomized-Controlled Trial of Acupuncture for Post-Mastectomy Pain Syndrome Scientific Title

Purpose

This study is investigating whether electro-acupuncture can help reduce pain women feel after their mastectomy.

Who is this for?

Women who had a mastectomy at least 4 months ago. You must have had persistent pain in your chest area for at least 3 months and have seen your oncologist within the last 6 months. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 3 groups: Group 1: Acupuncture on specific body points <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Up to 10 acupuncture sessions, over 4 weeks</li> <li class="seamTextUnorderedListItem">6 Questionnaires, over 8 weeks</li> </ul> Group 2: Acupuncture on non-specific body points <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Up to 10 acupuncture sessions, over 4 weeks</li> <li class="seamTextUnorderedListItem">6 Questionnaires, over 8 weeks</li> </ul> Group 3: Wait-List <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No acupuncture</li> <li class="seamTextUnorderedListItem">After 4 weeks, optional participation in up to 10 acupuncture sessions, over 4 weeks</li> <li class="seamTextUnorderedListItem">6 Questionnaires, over 8 weeks</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Electro-acupuncture is a two-step process. First, hair-thin needles are put into specific points in your body. Then, a mild electrical current is applied to the needles at a level that is comfortable to you.</li> </ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02754752' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 1655 miles
University of Iowa Hospitals and Clinics
Iowa City,IA

VISITS: Weekly visits for 3 months

PHASE: II

NCT ID: NCT03642990

Vitamin B3 to Reduce Paclitaxel-Related Peripheral Neuropathy in Metastatic Breast Cancer

Nicotinamide Riboside (NR) in Paclitaxel-induced Peripheral Neuropathy Scientific Title

Purpose

To determine whether nicotinamide riboside (Niagen®) prevents the progression of peripheral neuropathy.

Who is this for?

People with stage IV metastatic breast cancer that is being treated with paclitaxel (Taxol®). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Nicotinamide Riboside (Niagen®), by mouth, twice daily for 3 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Nicotinamide riboside (NR) is a vitamin B3 supplement. </li> <li class="seamTextUnorderedListItem">Studies suggest it may help prevent or treat nerve pain. </li> <li class="seamTextUnorderedListItem">Neuropathy--pain or numbness in the hands and feet--is a type of nerve pain. </li> <li class="seamTextUnorderedListItem">It is a common side effect of certain types of chemotherapy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03642990' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/side_effects/neuropathy' target='_blank'>Breastcancer.org: Neuropathy</a> </li><li class='seamTextUnorderedListItem'><a href='https://medcom.uiowa.edu/theloop/news/nicotinamide-riboside-vitamin-b3-prevents-nerve-pain-caused-by-cancer-drugs' target='_blank'>University of Iowa: Nicotinamide riboside (vitamin B3) prevents nerve pain caused by cancer drugs</a> </li></ul>

NEAREST SITE: 1728 miles
Mercy David C. Pratt Cancer Center
Saint Louis,MO

VISITS: Periodic visits for 3 years; then 1-3 visits per week for 1 month if needed

PHASE: NA

NCT ID: NCT03292198

L-Dex to Identify Breast Cancer-Related Lymphedema

Treatment Indications for Breast Cancer-related Subclinical Lymphedema Identified Through a Bioimpedance Surveillance Model Scientific Title

Purpose

To evaluate whether routine screening with L-Dex to detect lymphedema early improves patient outcomes.

Who is this for?

Women whose breast cancer surgery will include a sentinel lymph node biopsy or axillary lymph node dissection. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive periodic screening with L-dex for 3 years following surgery. If you develop lymphedema, you will be randomly assigned to 1 of 2 groups: Group 1: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Wear compression sleeves and gloves, daily, for 1 month</li> <li class="seamTextUnorderedListItem">L-dex measurement, weekly </li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Manual Lymphatic Drainage, 3 times per week, for 1 month</li> <li class="seamTextUnorderedListItem">Wear compression sleeves and gloves, daily, for 1 month</li> <li class="seamTextUnorderedListItem">L-dex measurement, weekly</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lymphedema is a common side effect after breast cancer surgery. </li> <li class="seamTextUnorderedListItem">It causes pain and swelling in the hands and arms. </li> <li class="seamTextUnorderedListItem">L-Dex is a portable system that uses a small electrical current to detect the build up of lymphatic fluid before it begins to cause side effects. </li> <li class="seamTextUnorderedListItem">Patients who develop lymphedema will be randomized to receive one of two treatment plans for breast cancer-related lymphedema.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03292198' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.nice.org.uk/advice/mib111/chapter/The-technology' target='_blank'>National Institute for Health and Care Excellence UK: L-Dex</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/lymphedema' target='_blank'>Breastcancer.org: Lymphedema</a> </li></ul>

NEAREST SITE: 1739 miles
Washington University School of Medicine
Saint Louis,MO

VISITS: At least 7 visits over 3 years

PHASE: II

NCT ID: NCT03862131

PROactive Evaluation to Reduce Treatment-Related Heart Problems (PROACT)

PROactive Evaluation of Function to Avoid CardioToxicity Scientific Title

Purpose

To look at whether MyoStrain® measurements are as good as or better than traditional MRI measurements for predicting and reducing a patient's risk of developing treatment-related heart problems.

Who is this for?

People with breast cancer and scheduled to start a cancer treatment. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cardiac MRI at 1 month, 3 months, 6 months, 1 year, 2 years, and 3 years after the baseline visit</li> <li class="seamTextUnorderedListItem">MyoStrain® measurements</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cardiac MRI at 1 month, 3 months, 6 months, 1 year, 2 years, and 3 years after the baseline visit</li> <li class="seamTextUnorderedListItem">Standard of care MRI measurements (LVEF and LVEDV/LVESV)</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MyoStrain® analyzes data collected from MRI heart scans to assess a patient's risk of developing heart problems.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03862131' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.myocardialsolutions.com/' target='_blank'>Sponsor site: MyoStrain®</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.nccn.org/patients/resources/life_with_cancer/managing_symptoms/cardiac_toxicity.aspx' target='_blank'>National Comprehensive Cancer Network: Cardiac Toxicity</a> </li></ul>

NEAREST SITE: 1856 miles
Northwestern University Feinberg School of Medicine
Chicago,IL

VISITS: 3 visits over 6 months

PHASE: II

NCT ID: NCT02513329

A Treatment to Reduce Hot Flashes in Women on Hormone Therapy

Effects of Stellate Ganglion Block (SGB) on Vasomotor Symptoms in Women Receiving Anti-Estrogen Therapy for Breast Cancer Scientific Title

Purpose

To allow researchers to learn whether a medication typically used as a local anesthetic helps reduce hot flashes. The researchers also want to see if the medication helps improve mood, memory, sleep, and quality of life.

Who is this for?

Women who have been taking a hormone (anti-estrogen) drug for at least 6 months. You must have 28 or more moderate-to-very severe hot flashes every week. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Bupivacaine, once by injection</li> <li class="seamTextUnorderedListItem">Diary, daily over 6 months</li> </ul> Group 2: Control <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Salt water (saline), once by injection</li> <li class="seamTextUnorderedListItem">Diary, daily over 6 months</li></ul>
Night sweats and hot flashes are two of the most common side effects women on hormone therapy experience. <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The medicine being used in this study is called bupivacaine.</li> </ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02513329' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 1857 miles
University of Chicago
Chicago,IL

VISITS: 1 visit

PHASE: NA

NCT ID: NCT03238976

Nature Sounds to Reduce Pain and Anxiety During a Breast Core Needle Biopsy

Nature Sounds as a Pain and Anxiety Reducing Strategy in Patients Undergoing Breast Core Biopsy: A Randomized Study Scientific Title

Purpose

To investigate the effects (good and bad) playing continuous nature sounds during a core needle biopsy has on a patient's pain and anxiety.

Who is this for?

Women scheduled to have a breast core needle biopsy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive continuous nature sounds during core needle biopsy</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive supportive dialogue during core needle biopsy</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A core needle biopsy is a procedure that removes a small amount of suspicious tissue from the breast with a needle.</li> </ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03238976' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ww5.komen.org/BreastCancer/CoreNeedleBiopsy.html' target='_blank'>Susan G. Komen: Core Needle Biopsy</a> </li></ul>

NEAREST SITE: 2064 miles
University of Toledo
Toledo,OH

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT04232319

Online Program with an Occupational Therapist for Women Who Have Been Treated for DCIS, Stage I, Stage II, or Stage III Breast Cancer and Have Sleep Problems

Feasibility of a Sleep Hygiene Education Program for Sleep Issues in Breast Cancer Survivors Scientific Title

Purpose

To evaluate whether an online program with an occupational therapist who teaches sleep hygiene can improve quality of sleep.

Who is this for?

Women who were treated for DCIS, stage I, stage II, or stage III breast cancer who are not receiving chemotherapy or radiation, are having sleep problems, and are not taking a pharmacological sleep aide. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Online session with an occupational therapist, weekly, for 30 to 45 minutes, for 3 weeks</li> <li class="seamTextUnorderedListItem">A workbook about sleep hygiene (habits) and strategies to improve quality of sleep</li> <li class="seamTextUnorderedListItem">Help from the occupational therapist about how to apply different sleep habits and strategies from the workbook</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study will evaluate whether an online program with an occupational therapist who teaches sleep hygiene can improve quality of sleep.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04232319' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.sleepfoundation.org/articles/sleep-hygiene' target='_blank'>SleepFoundation.org: What is Sleep Hygiene?</a> </li></ul>

NEAREST SITE: 2108 miles
Ohio State University Comprehensive Cancer Center
Columbus,OH

VISITS: Number of visits unavailable, over 5 weeks

PHASE: II

NCT ID: NCT03786354

3D Radiation Therapy To Reduce Side Effects For Lymph-Node Positive Breast Cancer

Prospective Evaluation of Shoulder Morbidity in Patients With Lymph-Node Positive Breast Cancer Receiving Regional Nodal Irradiation Scientific Title

Purpose

To compare the shoulder- and upper arm-related side effects of intensity-modulated radiation therapy to those of 3-dimensional conformal radiation therapy.

Who is this for?

Women with stage II or stage III breast cancer who have had a lumpectomy or a mastectomy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Intensity-Modulated Radiation Therapy (IMRT), over 5 weeks</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">3-Dimensional Conformal Radiation Therapy (3DCRT), over 5 weeks</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation therapy can affect the muscles in the shoulder and upper arm. </li> <li class="seamTextUnorderedListItem">Intensity-modulated radiotherapy (IMRT) is a widely used type of radiation therapy. </li> <li class="seamTextUnorderedListItem">3-dimensional conformal radiation therapy (3DCRT) is a newer type of radiation therapy that may result in fewer side effects.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03786354' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ascopost.com/issues/july-10-2016/managing-upper-extremity-dysfunction-in-breast-cancer-survivors/' target='_blank'>ASCO Post: Managing Upper Extremity Dysfunction in Breast Cancer Survivors</a> </li><li class='seamTextUnorderedListItem'><a href='https://conquer-magazine.com/categories/breast-cancer/394-shoulder-pain-and-breast-cancer' target='_blank'>Conquer: Shoulder Pain and Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.healthline.com/health/breast-cancer/why-do-i-have-arm-shoulder-pain' target='_blank'>Heathline: Breast Cancer: Why Do I Have Arm and Shoulder Pain?</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.radiologyinfo.org/en/info.cfm?pg=imrt' target='_blank'>UCSF Radiology: Intensity-Modulated Radiation Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://radonc.ucsf.edu/three-dimensional-conformal-radiation-therapy-3dcrt' target='_blank'>UCSF Radiology: 3-Dimensional Conformal Radiation Therapy</a> </li></ul>

NEAREST SITE: 2108 miles
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
Columbus,OH

VISITS: Visits weekly

PHASE: II

NCT ID: NCT02203552

Antibiotic to Prevent Memory Problems, Anxiety & Depression in Patients on Adriamycin

Randomized Placebo Controlled Study of Minocycline for Amelioration of Chemotherapy Induced Affective Disorders Scientific Title

Purpose

To see if giving the drug Minocycline (Minocin) to women who are receiving Adriamycin will keep side effects such as problems with memory and thinking skills, anxiety, and/or depression, from developing.

Who is this for?

Women with stage I, stage II, or stage III breast cancer who are schedule to receive adriamycin chemotherapy before or after breast cancer surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Minocycline (Minocin), by mouth, twice daily for 9 weeks</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo, by mouth, twice daily for 9 weeks</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Women who receive the chemotherapy drug doxorubicin (Adriamycin®) as part of their breast cancer treatment may develop problems with their memory and thinking skills, anxiety, and/or depression. </li> <li class="seamTextUnorderedListItem">Researchers think giving the drug Minocycline (Minocin) to women who are receiving Adriamycin may keep these side effects from developing. </li> <li class="seamTextUnorderedListItem">Minocin is is an antibiotic you take by mouth to treat infections.</li> </ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02203552' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://clinicaltrials.gov/show/NCT02203552' target='_blank'>ClinicalTrials.gov: Trial Information</a> </li></ul>

NEAREST SITE: 2108 miles
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Wexner Medical Center
Columbus,OH

VISITS: At least 2 visits

PHASE: NA

NCT ID: NCT02415387

Typhoid Vaccine to Study Immune Response in Patients Who Received Chemotherapy

The IMPACT Study: Inflammatory Responses, Mood and Physical Fitness After Cancer Treatment Scientific Title

Purpose

To investigate how women who have completed treatment for early-stage breast cancer respond to a typhoid vaccine by measuring their cardiorespiratory fitness, natural inflammatory reaction, and behavioral responses such as depression, fatigue, pain, and problems with thinking and reasoning.

Who is this for?

Women who are postmenopausal and have received chemotherapy as part of breast cancer treatment. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

Participants will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Typhoid vaccine, by injection, on first visit</li> <li class="seamTextUnorderedListItem">followed by placebo, by injection, on second visit (2 weeks to 1 month later)</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo, by injection, on first visit</li> <li class="seamTextUnorderedListItem">followed by typhoid vaccine, by injection, on second visit (2 weeks to 1 month later)</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Chemotherapy can weaken the body's immune system. </li> <li class="seamTextUnorderedListItem">Physical fitness may protect the body from the effects that chemotherapy has on the immune system as well as reduce other health problems. </li> <li class="seamTextUnorderedListItem">Giving patients a typhoid vaccine allows researchers to study their immune response.</li> </ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02415387' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2258 miles
University of Pittsburgh
Pittsburgh,PA

VISITS: Visits 3 times a week over 6 months

PHASE: NA

NCT ID: NCT02793921

An Exercise Program to Improve Thinking and Memory in Women on an Aromatase Inhibitor

Influence of Exercise on Neurocognitive Function in Breast Cancer Scientific Title

Purpose

To see if taking part in a supervised aerobic exercise program during the first 6 months on an aromatase inhibitor will help improve thinking, memory, learning, attention and other brain functions.

Who is this for?

Women who have had surgery for stage I, stage II, or stage III breast cancer and are planning to start on a type of anti-estrogen drug called an aromatase inhibitor. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Intervention <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A supervised aerobic exercise program, 3 times a week, during the first 6-months of aromatase inhibitor therapy</li> </ul> Group 2: Control <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Normal physical activity (neither limited or withheld), during the first 6-months of aromatase inhibitor therapy</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Problems with thinking, memory and other brain functions are a common side effect of the aromatase inhibitors. </li> <li class="seamTextUnorderedListItem">The aromatase inhibitors are anastrozole (Arimidex®), letrozole (Femara®), and exemestane (Aromasin®). </li> <li class="seamTextUnorderedListItem">All three are used to treat hormone receptor positive (ER+ and/or PR+) tumors in postmenopausal women.</li> </ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02793921' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2314 miles
Wake Forest University Health Sciences
Winston-Salem,NC

VISITS: 9 visits over 3 months

PHASE: NA

NCT ID: NCT03505671

Acupuncture for Neuropathy (Hand/Foot Pain) Caused by Chemo for Stage I-III Breast Cancer

Acupuncture for Chemotherapy-Induced Peripheral Neuropathy Among Breast Cancer Patients Scientific Title

Purpose

To see if acupuncture can help reduce pain from peripheral neuropathy.

Who is this for?

Women with stage I, II or III breast cancer and currently receiving a taxane-based chemotherapy either before surgery (neoadjuvant therapy) or after surgery (adjuvant therapy). You must also have begun to develop peripheral neuropathy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">8 acupuncture treatments (45 minutes) over 2.5 months</li> <li class="seamTextUnorderedListItem">Follow-up visit at 3 months </li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 2: Standard of care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care</li> <li class="seamTextUnorderedListItem">Follow-up visit at 3 months </li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Peripheral neuropathy--pain and numbness in the hands and feet--is a common side effect of chemotherapy regimens that include a taxane. </li> <li class="seamTextUnorderedListItem">This study is designed to see if acupuncture can help reduce this type of pain.</li> <li class="seamTextUnorderedListItem">Acupuncture is a type of Chinese medicine that involves inserting hair-thin needles into specific points on the body.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03505671' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/peripheral-neuropathy.html' target='_blank'>American Cancer Society: Peripheral Neuropathy Caused by Chemotherapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.medscape.com/viewarticle/755026' target='_blank'>Medscape: Acupuncture Soothes Chemo-Induced Neuropathic Pain</a> </li></ul>

NEAREST SITE: 2352 miles
University of Rochester
Rochester,NY

VISITS: 5 visits over 3-5 months

PHASE: NA

NCT ID: NCT03137095

Memory Problems During Chemotherapy in Patients with Stage I-III Breast Cancer

Longitudinal Pilot Mechanistic Study of the Effects of Chemotherapy on Cognitive Function in Breast Cancer Patients and Non-Cancer Control Participants Scientific Title

Purpose

To see if and how your cognitive functioning skills, like memory and concentration, change as you receive chemotherapy.

Who is this for?

Women who have been recently diagnosed with stage I, stage II, or stage III breast cancer who are planning to receive chemotherapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will undergo the following over 3-5 months: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">3 computerized and paper-based cognitive tests during chemotherapy and 1 month after completion of chemotherapy</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers will give you cognitive tests during your chemotherapy treatment and one month after you have completed treatment.</li> </ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03137095' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2352 miles
University of Rochester NCORP Research Base
Rochester,NY

VISITS: Number of visits unavailable

PHASE: III

NCT ID: NCT03367572

Combinations of Antiemetics for Reducing Chemotherapy-Induced Nausea and Vomiting

Treatment of Refractory Nausea Scientific Title

Purpose

To study which combination of antiemetic drugs is most effective in reducing nausea and vomiting that often occur in patients receiving chemotherapy.

Who is this for?

Women diagnosed with breast cancer but who have not yet started chemotherapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 3 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Netupitant/palonosetron hydrochloride, by mouth, within 1 hour prior to receiving chemotherapy, on day 1 </li> <li class="seamTextUnorderedListItem">Dexamethasone, by mouth, within 30 minutes prior to chemotherapy, days 1-4 </li> <li class="seamTextUnorderedListItem">Placebo, by mouth, every 8 hours with chemotherapy, days 1-4 </li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Netupitant/palonosetron hydrochloride, by mouth, within 1 hour prior to receiving chemotherapy, on day 1 </li> <li class="seamTextUnorderedListItem">Dexamethasone, by mouth, within 30 minutes prior to chemotherapy, days 1-4 </li> <li class="seamTextUnorderedListItem">Prochlorperazine and placebo, by mouth, every 8 hours with chemotherapy, days 1-4 </li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Netupitant/palonosetron hydrochloride, by mouth, within 1 hour prior to receiving chemotherapy, on day 1 </li> <li class="seamTextUnorderedListItem">Dexamethasone, by mouth, within 30 minutes prior to chemotherapy, days 1-4 </li> <li class="seamTextUnorderedListItem">Olanzapine and placebo, by mouth, every 8 hours with chemotherapy, days 1-4</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The antiemetic drugs being used in this study are netupitant/palonsetron hydrochloride (Akynzeo), dexamethasone (Decadrone), prochlorperazine, and olanzapine (Zyprexa).</li> </ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03367572' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/research-news/updated-asco-guidelines-on-antiemetics' target='_blank'>ASCO: Guidelines to treat nausea and vomiting</a> </li></ul>

NEAREST SITE: 2371 miles
University of Florida Proton Therapy Institute
Jacksonville,FL

VISITS: 2 visits over 1 year

PHASE: NA

NCT ID: NCT02199366

Using MRI of the Heart to Study Effects of Radiation Therapy for Left-Sided Breast Cancer

Prospective Pilot Study of Early Markers of Radiation-Induced Cardiac Injury in Patients With Left-Sided Breast Cancer Receiving Photon or Proton Therapy Scientific Title

Purpose

To study whether MRI scans of the heart can identify changes in heart function that develop after radiation therapy.

Who is this for?

People who are scheduled to receive radiation therapy for a stage I, stage II, or stage III, left-sided breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

All participants will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">2 MRI scans of the heart, before radiation therapy and within 1 year after completion of radiation therapy</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">People who receive radiation therapy to treat breast cancer in their left breast are at risk of developing heart problems. </li> <li class="seamTextUnorderedListItem">Magnetic Resonance Imaging (MRI) scans produce detailed images of the inside of the body.</li> </ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02199366' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/symptoms/testing/types/mri' target='_blank'>BreastCancer.org: MRI</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/research-news/20070809b' target='_blank'>BreastCancer.org: Radiation and Heat Problem</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/treatment/radiation/when_appropriate' target='_blank'>BreastCancer.org: Radiation</a> </li></ul>

NEAREST SITE: 2433 miles
Sibley Memorial Hospital
Washington,DC

VISITS: 10 visits over 6 weeks

PHASE: NA

NCT ID: NCT03143894

Non-Invasive Brain Stimulation to Reduce Fatigue & Improve Thinking Skills

Reducing Breast Cancer-related Fatigue and Improving Cognition With Non-Invasive Brain Stimulation Scientific Title

Purpose

To learn whether non-invasive brain stimulation reduces fatigue and improves thinking skills in breast cancer survivors.

Who is this for?

Women who have completed breast cancer treatment within the past 6 months to 5 years and have persistent fatigue. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">30-minute brain stimulation, once daily for 5 consecutive days; twice over 6 weeks</li> <li class="seamTextUnorderedListItem">Follow-up questionnaire by phone, 1 week later</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">30-minute sham stimulation, once daily for 5 consecutive days; twice over 6 weeks</li> <li class="seamTextUnorderedListItem">Follow-up questionnaire by phone, 1 week later</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The brain stimulation technique is called transcranial direct current stimulation (tDCS). </li> <li class="seamTextUnorderedListItem">Previous studies have found it can improve fatigue and thinking skills.</li> </ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03143894' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Transcranial_direct-current_stimulation' target='_blank'>Wikipedia: Transcranial direct-current stimulation (tDCS)</a> </li></ul>

NEAREST SITE: 2434 miles
Georgetown University
Washington,DC

VISITS: 1 visit

PHASE: NA

NCT ID: NCT03091647

Acupressure for Chinese Immigrant Breast Cancer Survivors

Acupressure Intervention to Improve Fatigue and Physical Functioning of Chinese Immigrant Breast Cancer Survivors Scientific Title

Purpose

To see whether using a Chinese-language video to teach how to self-administer acupressure helps improve cancer-related fatigue and quality of life better than the current standard of care.

Who is this for?

You must have been treated for DCIS or Stage I, II, or III breast cancer within the last 1 to 5 years and have moderate to severe levels of fatigue. You must be a first-generation immigrant who speaks Chinese (Mandarin or Cantonese) living in or near Los Angeles, California. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Acupressure <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Learn acupressure practice from an instructional video in Chinese </li> <li class="seamTextUnorderedListItem">Self-administer acupressure and record practice in a log, daily, for 2 months</li> <li class="seamTextUnorderedListItem">2 phone interviews, at baseline and at follow-up </li> </ul> Group 2: Control <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care support </li> <li class="seamTextUnorderedListItem">Record fatigue and functioning levels in a log, daily, for 2 months </li> <li class="seamTextUnorderedListItem">2 phone interviews, at baseline and at follow-up</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Acupressure is a common treatment in traditional Chinese medicine. It is similar to acupuncture but does not use needles. </li> </ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03091647' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2434 miles
Lombardi Comprehensive Cancer Center
Washington,DC

VISITS: Coincides with chemotherapy treatment

PHASE: II

NCT ID: NCT02910219

Preventing Diarrhea in Patients Being Treated for HER2+ Breast Cancer

Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients Receiving Trastuzumab, Pertuzumab, and Docetaxel or Paclitaxel With or Without Carboplatin: HALT-D Scientific Title

Purpose

To see if an anti-diarrhea medicine can help prevent chemotherapy-induced diarrhea in HER2+ breast cancer patients.

Who is this for?

People with any stage of HER2 positive breast cancer who are scheduled to receive either THP or TCHP therapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups during the first 2 cycles of chemotherapy with THP or TCHP: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Crofelemer (Mytesi®), by mouth, daily</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No intervention</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The anti-diarrhea medicine being used in this study is Crofelemer (Mytesi®). It is used to prevent diarrhea in HIV/AIDS patients. </li> <li class="seamTextUnorderedListItem">The THP chemotherapy regimen contains docetaxel (Taxotere®), trastuzumab (Herceptin®), and pertuzumab (Perjeta®). </li> <li class="seamTextUnorderedListItem">The TCHP regimen contains docetaxel (Taxotere®), carboplatin (Paraplatin®), trastuzumab (Herceptin®), and pertuzumab (Perjeta®).</li> </ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02910219' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.fulyzaq.com/' target='_blank'>Crofelemer (Mytesi®)</a> </li></ul>

NEAREST SITE: 2452 miles
Baltimore VA Medical Center
Baltimore,MD

VISITS: Visits 3 times a week for 3 months

PHASE: NA

NCT ID: NCT02991677

Effect of Exercise on Chemotherapy-Related Pain and Numbness in Hands and Feet

Exercise Effect on Chemotherapy-Induced Neuropathic Pain, Peripheral Nerve Fibers Scientific Title

Purpose

To investigate whether aerobic exercise or resistance training exercise can help decrease chemotherapy-related peripheral neuropathy.

Who is this for?

People with stage I, stage II, stage III and stage IV breast cancer who were treated with oxaliplatin (Eloxitin®), docetaxel (Taxotere®) or paclitaxel (Taxol®). You must have completed this chemotherapy between 6 months and 1 year prior to study enrollment. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 3 groups: Group 1 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Aerobic exercise, 3 times a week for 3 months</li> </ul> Group 2 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Resistive training exercise, 3 times a week for 3 months</li> </ul> Group 3 <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No exercise intervention</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Certain types of chemotherapy drugs can cause patients to develop peripheral neuropathy-pain and numbness in the hands and feet. </li> <li class="seamTextUnorderedListItem">Aerobic exercise or resistance training exercise may help decrease chemotherapy-related peripheral neuropathy.</li> <li class="seamTextUnorderedListItem">The aerobic exercise program will involve walking or running on a treadmill. </li> <li class="seamTextUnorderedListItem">The resistance training will use muscles in your upper-body and lower-body. </li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02991677' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/treatment/side_effects/neuropathy' target='_blank'>Breastcancer.org: Neuropathy</a> </li></ul>

NEAREST SITE: 2561 miles
Memorial Sloan Kettering Bergen
Montvale,NJ

VISITS: 8 to 10 times for 2-3 years, then once a year for 2-3 years

PHASE: NA

NCT ID: NCT00823654

Measuring Hormone Levels to Study How Cancer Treatments & Inherited BRCA 1/2 Mutations Affect The Ovaries

Multi-Center Study of Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer and Lymphoma Scientific Title

Purpose

To study if a blood test that measures hormones can predict who will enter early menopause or develop fertility issues because of how chemotherapy and hormone therapy affect the ovaries; and to study the fertility and sexual health of women with inherited BRCA 1 or BRCA 2 mutations.

Who is this for?

Premenopausal women, 44 or younger, with DCIS or stage I, stage II, or stage III breast cancer planning to receive chemotherapy or tamoxifen. You may also enroll if you do not have breast cancer but have an inherited BRCA 1 or BRCA 2 mutation. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be assigned to 1 of 2 groups: Group 1: Women with DCIS or stage I-III breast cancer <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood draws, 8-10 times for 2-3 years, then once a year for 2-3 years (5 years total)</li> </ul> Group 2: Women with inherited BRCA mutations <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood draws, 5 times for the first year, then optional draws once a year for 4 years (5 years total)</li> </ul> Additional procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer treatments can affect the ovaries, which may cause early menopause or difficulty becoming pregnant. </li> <li class="seamTextUnorderedListItem">Ovarian functioning can be assessed by evaluating the blood levels of certain hormones the ovaries produce.</li> <li class="seamTextUnorderedListItem">Inherited BRCA 1/2 mutations may affect your ovaries.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT00823654' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.youngsurvival.org' target='_blank'>Young Survival Coalition</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.facingourrisk.org/index.php' target='_blank'>FORCE: Facing Our Risk of Cancer Empowered</a> </li></ul>

NEAREST SITE: 2569 miles
Icahn School of Medicine at Mount Sinai
New York,NY

VISITS: 3 visits over 1.5 months

PHASE: NA

NCT ID: NCT02657993

Hypnosis for Reducing Pain Associated With Aromatase Inhibitors

Hypnosis to Reduce Aromatase Inhibitor (AI) Associated Musculoskeletal Pain and to Improve AI Adherence: An RCT to Explore Efficacy and Cost Effects Scientific Title

Purpose

To see if hypnosis reduces aromatase inhibitor-related pain and to compare the effects (good and bad) of hypnosis to empathetic listening for pain reduction.

Who is this for?

Women with DCIS or stage I, stage II, or stage III breast cancer who are currently taking an aromatase inhibitor. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

Participants will be randomly assigned to 1 of 2 groups: Group 1: Hypnosis <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">3 hypnosis sessions over 1.5 months</li> <li class="seamTextUnorderedListItem">Hypnosis recording to use in between sessions, at home</li> </ul> Group 2: Empathetic Listening <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">3 non-hypnosis empathetic listening sessions over 1.5 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Aromatase inhibitors are used to treat hormone receptor positive (ER+ and/or PR+) breast cancer in postmenopausal women. </li> <li class="seamTextUnorderedListItem">Muscle pain, joint pain and decreased grip strength are some of the most common side effects of these medications.</li> <li class="seamTextUnorderedListItem">These side effects can reduce quality of life and lead women to stop taking their aromatase inhibitors. </li> <li class="seamTextUnorderedListItem">Hypnosis is a mind-body intervention that has been shown to reduce pain.</li> </ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02657993' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://clinicaltrials.gov/ct2/show/NCT02657993' target='_blank'>ClinicalTrials.gov: Trial Information</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancerresearchuk.org/about-cancer/cancers-in-general/treatment/complementary-alternative/therapies/hypnotherapy' target='_blank'>Hypnotherapy for Cancer Pain</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.mountsinai.org/profiles/julie-b-schnur' target='_blank'>Mount Sinai: Dr. Schnur</a> </li></ul>

NEAREST SITE: 2569 miles
Memorial Sloan Kettering Cancer Center
New York,NY

VISITS: Coincides with standard treatment

PHASE: NA

NCT ID: NCT02530177

Effect of Chemo & Hormone Therapy on Hair, Skin & Nails in Early-Stage Breast Cancer

A Prospective, Longitudinal Study of Chemotherapy-Induced Hair Changes and Alopecia, Skin Aging and Nail Changes in Women With Non-Metastatic Breast Cancer Scientific Title

Purpose

To see if there are certain clinical factors or genetic markers that can help predict which women are most likely to develop skin, hair or nail problems.

Who is this for?

Women with DCIS or stage I, stage II or stage III breast cancer who are about to start treatment with chemotherapy or hormone therapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

All participants will undergo study-related assessments and fill out questionnaires related to breast cancer treatment at standard-of-care visits.
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study is looking at the effect that chemotherapy and hormone therapy have on the skin, hair and nails.</li> </ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02530177' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ClinicalTrials.gov/show/NCT02530177' target='_blank'>ClinicalTrials.gov trial info</a> </li></ul>

NEAREST SITE: 2691 miles
Massachusetts General Hospital
Boston,MA

VISITS: Coincides with standard follow-up care

PHASE: NA

NCT ID: NCT01521741

Impact of Lymphedema on Quality of Life after Breast Cancer

Prospective Analysis of Symptoms, Functionality and Quality of Life Questionnaires to Evaluate Lymphedema in Patients Following Treatment for Breast Cancer. Scientific Title

Purpose

To determine how the symptoms and functional disability that accompany lymphedema can impact breast cancer survivors' quality of life.

Who is this for?

Women with breast cancer and without brain metastasis or axillary lymph node malignancy Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

All participants will complete the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires and arm measurements</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer treatments can result in long-term, painful swelling of the arm and hand, a condition called lymphedema. </li> <li class="seamTextUnorderedListItem">To be eligible, participants must be planning to have surgery and receive follow-up care for breast cancer at Massachusetts General Hospital.</li> </ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01521741' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/search.jsp?terms=lymphedema' target='_blank'>BreastCancer.org: Lymphedema</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.gov/cancertopics/pdq/supportivecare/lymphedema/Patient/page1' target='_blank'>NCI: Lymphedema</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.org/Treatment/TreatmentsandSideEffects/PhysicalSideEffects/Lymphedema/WhatEveryWomanwithBreastCancerShouldKnow/lymphedema-what-every-woman-with-breast-cancer-should-know-toc' target='_blank'>ACS: Lymphedema</a> </li></ul>

NEAREST SITE: 2693 miles
Beth Israel Deaconess Medical Center
Boston,MA

VISITS: Number of visits unavailable, over 1 year

PHASE: NA

NCT ID: NCT02666378

Detecting Treatment-Related Cardiotoxicity in HER2 Positive Breast Cancer

Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer Scientific Title

Purpose

To determine whether Cardiac Magnetic Resonance Imaging (CMR) and Echocardiogram (ECHO) tests can be used to identify early signs of heart problems that can be caused by Doxil and Herceptin.

Who is this for?

Women with HER2 positive breast cancer who are going to be treated with doxorubicin (Doxil®) and trastuzumab (Herceptin®) after surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will undergo the following before treatment with chemotherapy and at predetermined times during and after treatment: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI (Cardiac Magnetic Resonance Imaging, CMR)</li> <li class="seamTextUnorderedListItem">Ultrasound (Echocardiogram, ECHO)</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study is investigating whether Cardiac Magnetic Resonance Imaging (CMR) and Echocardiogram (ECHO) tests can be used to identify early signs of heart problems that can be caused by Doxil and Herceptin.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02666378' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/20111005' target='_blank'>Breastcancer.org: Herceptin Related Heart Damage</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/heart-meds-reduce-herceptin-cardiac-damage' target='_blank'>Breastcancer.org: Medicine for Herceptin Related Heart Damage</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/tx-w-herceptin-needs-heart-monitoring' target='_blank'>Breastcancer.org: Women Treated With Herceptin Need Heart Monitoring</a> </li></ul>

No Travel Required

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT04160182

Online Program with an Occupational Therapist to Help Women Treated for DCIS, Stage I, Stage II, or Stage III Breast Cancer Manage Fatigue

Feasibility and Effectiveness of an Internet-based Intervention to Manage Fatigue in Breast Cancer Survivors Scientific Title

Purpose

To evaluate whether six weeks of online meetings with an occupational therapist who teaches fatigue management skills helps reduce fatigue or the effects of fatigue on quality of life.

Who is this for?

Women who were treated for DCIS, stage I, stage II, or stage III breast cancer who are currently not receiving chemotherapy or radiation, are experiencing fatigue, and are not taking medications for depression, sleep issues, or fatigue. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Online sessions with an occupational therapist, 45 minutes each, weekly, for 6 weeks</li> <li class="seamTextUnorderedListItem">A workbook containing information, strategies, and skills to help you manage your fatigue</li> <li class="seamTextUnorderedListItem">Help from the occupational therapist in applying these skills to your life</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fatigue is a common side effect of breast cancer treatment.</li> <li class="seamTextUnorderedListItem">This study will evaluate whether six weeks of online meetings with an occupational therapist who teaches fatigue management skills helps reduce fatigue or the effects of fatigue on quality of life.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04160182' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/side_effects/fatigue' target='_blank'>Breastcancer.org: Fatigue</a> </li></ul>

Browse Trials

Narrow my choices:

Diarrhea Prevention for People With HER2+ Breast Cancer Receiving Neratinib Alone or With Herceptin

Contact Research Sites

Aricept to Improve Memory Loss in Survivors Who Had Chemotherapy

Contact Research Sites

Neratinib & Imodium after Herceptin for HER2+ Stage I-III Breast Cancer

Contact Research Sites

CSF to Prevent Neutropenia (Infection) Caused by Chemotherapy (TrACER)

Contact Research Sites

Carvedilol to Prevent Heart Problems in Patients with Metastatic HER2+ Breast Cancer

Contact Research Sites

Low-Calorie Diet To Reduce Side Effects of Chemotherapy

Contact Research Sites

High-Intensity Interval Training for Patients with Early-Stage Breast Cancer

Contact Research Sites

Physical Therapy to Prevent Peripheral Neuropathy in Women with Early-Stage Breast Cancer

Contact Research Sites

Using Brain Imaging to Study the Effect of Chemotherapy on the Brain

Contact Research Sites

Syndros to Reduce Pain from Bone Metastases in Stage IV Breast Cancer

Contact Research Sites

Hypofractionated Radiation To Treat Regional Lymph Nodes to Reduce Lymphedema Risk

Contact Research Sites

Effects of Hypnosis During Breast Cancer Surgery

Contact Research Sites

Acupuncture for Relieving Severe Post-Mastectomy Pain

Contact Research Sites

Vitamin B3 to Reduce Paclitaxel-Related Peripheral Neuropathy in Metastatic Breast Cancer

Contact Research Sites

L-Dex to Identify Breast Cancer-Related Lymphedema

Contact Research Sites

PROactive Evaluation to Reduce Treatment-Related Heart Problems (PROACT)

Contact Research Sites

A Treatment to Reduce Hot Flashes in Women on Hormone Therapy

Contact Research Sites

Nature Sounds to Reduce Pain and Anxiety During a Breast Core Needle Biopsy

Contact Research Sites

Online Program with an Occupational Therapist for Women Who Have Been Treated for DCIS, Stage I, Stage II, or Stage III Breast Cancer and Have Sleep Problems

Contact Research Sites

3D Radiation Therapy To Reduce Side Effects For Lymph-Node Positive Breast Cancer

Contact Research Sites

Antibiotic to Prevent Memory Problems, Anxiety & Depression in Patients on Adriamycin

Contact Research Sites

Typhoid Vaccine to Study Immune Response in Patients Who Received Chemotherapy

Contact Research Sites

An Exercise Program to Improve Thinking and Memory in Women on an Aromatase Inhibitor

Contact Research Sites

Acupuncture for Neuropathy (Hand/Foot Pain) Caused by Chemo for Stage I-III Breast Cancer

Contact Research Sites

Memory Problems During Chemotherapy in Patients with Stage I-III Breast Cancer

Contact Research Sites

Combinations of Antiemetics for Reducing Chemotherapy-Induced Nausea and Vomiting

Contact Research Sites

Using MRI of the Heart to Study Effects of Radiation Therapy for Left-Sided Breast Cancer

Contact Research Sites

Non-Invasive Brain Stimulation to Reduce Fatigue & Improve Thinking Skills

Contact Research Sites

Acupressure for Chinese Immigrant Breast Cancer Survivors

Contact Research Sites

Preventing Diarrhea in Patients Being Treated for HER2+ Breast Cancer

Contact Research Sites

Effect of Exercise on Chemotherapy-Related Pain and Numbness in Hands and Feet

Contact Research Sites

Measuring Hormone Levels to Study How Cancer Treatments & Inherited BRCA 1/2 Mutations Affect The Ovaries

Contact Research Sites

Hypnosis for Reducing Pain Associated With Aromatase Inhibitors

Contact Research Sites

Effect of Chemo & Hormone Therapy on Hair, Skin & Nails in Early-Stage Breast Cancer

Contact Research Sites

Impact of Lymphedema on Quality of Life after Breast Cancer

Contact Research Sites

Detecting Treatment-Related Cardiotoxicity in HER2 Positive Breast Cancer

Contact Research Sites

Online Program with an Occupational Therapist to Help Women Treated for DCIS, Stage I, Stage II, or Stage III Breast Cancer Manage Fatigue

Contact Research Sites

Connect

Site Map